

SwitchGene: Eye drop activated gene therapy

Market: Wet AMD and diabetic retinopathy are major causes of blindness. 90 million affected worldwide by 2045 with an economic burden of >\$450B USD

Current Solution: Anti-VEGF injections (and recently port devices). Only current treatment to block VEGF for AMD and diabetic macular edema (DME).

Problem:

- Frequent injections
- Treats new blood vessel growth only
- Vision declines in wet AMD despite treatment

Our therapy: Innovative platform for anti-VEGF therapy. Designed to neutralise both intracellular and extracellular VEGF.

Unique ability to selectively boost anti-VEGF activity with a topical eye drop.

Next Steps:

Further in-vivo pre-clinical validation:


- Head-to-head comparison with current standard of care, and validate dual-action gene therapy
- Strategic partnership opportunity to accelerate validation. Contact: stan@cera.org.au



A/Prof. Rick Liu



Dr. Flora Hui



POC *in-vivo* mouse models of diabetic disease (Akita) and humanised proliferative retinopathy (Kimba).

(A) Protects retinal function

(B) Reduces retinal vessel growth with eyedrop activation